Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
MA

NASDAQ · MAZE

Maze Therapeutics, Inc.

Healthcare · Biotechnology

$26.43

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 8:48 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.9B
P/E ratio
-14.34
Dividend yield
0.00%
52-week range
$21.95 – $53.65
Volume
682.84K
Avg. volume
535.35K

Price performance · MAZE

MAZE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

MAZE closed at $26.43 after 21 trading sessions, up 0.23% for the selected period.

Last close
$26.43
Period change
+0.23%
Period low
$22.39
Period high
$28.38
Daily close
View OHLC price history
MAZE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$26.74$26.91$25.785$26.43682.84K
Oct 5, 2026$26.67$27.03$25.78$26.43588.01K
Oct 2, 2026$27.08$27.49$26.36$26.43633.05K
Oct 1, 2026$27.05$27.79$26.50$26.65589.35K
Sep 30, 2026$27.21$28.02$26.95$27.18518.01K
Sep 29, 2026$26.77$27.55$26.47$27.02709.49K
Sep 28, 2026$25.97$27.7319$24.84$26.851.18M
Sep 25, 2026$26.23$27.79$25.42$26.05925.61K
Sep 24, 2026$28.42$28.46$25.96$26.21789.25K
Sep 23, 2026$28.30$29.91$27.53$28.091.7M
Sep 22, 2026$24.52$29.40$24.50$28.383.57M
Sep 21, 2026$22.52$23.015$21.95$22.39516.97K
Sep 18, 2026$23.27$23.565$22.01$22.521.49M
Sep 17, 2026$24.38$24.80$23.27$23.44363.52K
Sep 16, 2026$24.33$24.72$23.74$23.915385.69K
Sep 15, 2026$24.63$24.795$24.00$24.23437.4K
Sep 14, 2026$24.90$25.85$24.46$24.67589.28K
Sep 11, 2026$25.14$25.99$24.36$24.601.05M
Sep 10, 2026$24.26$25.62$23.9401$24.821.18M
Sep 9, 2026$25.86$26.545$24.39$24.58401.49K
Sep 8, 2026$25.76$26.57$25.30$26.37365.3K

Latest MAZE news

The latest Smart Investors Daily articles mentioning MAZE.

Stock researchCompany · Overview

MAZE research

Overview

Company profile and research snapshot.

Company profile

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$40.67
Implied upside
—
Analysts
—
MAZE recent ratings
DateFirmRatingTarget
Sep 24, 2026HC Wainwright & Co.Buy—
Sep 23, 2026CitigroupBuy—
Sep 23, 2026WedbushOutperform—
Sep 22, 2026BTIGBuy—
Aug 12, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

Yahoo · Sep 25, 2026

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?

Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By